Abstract:Abstract Cutaneous adverse events with immune checkpoint inhibitors (ICI) are common and their spectrum is ever expanding. We describe the first case of photosensitivity associated with the anti-programmed death ligand (PDL)1 inhibitor durvalumab for transitional cell carcinoma (TCC) of the bladder, which recurred with subsequent use of the anti-PDL1 inhibitor avelumab. A 73-year-old South Asian male patient developed an intensely itchy photosensitive rash. He had a completely resected bladder TCC and was recruited to a clinical trial for residual TCC in situ and randomized to durvalumab infusions (with intravesical bacille Calmette–Guérin). The rash developed after the second infusion; its severity required oral prednisolone 1 mg kg−1 per day started by oncology. He had a lichenoid and profoundly hyperpigmented rash affecting his face, neck, hands and feet with no other clinical features of dermatomyositis. Skin biopsy demonstrated a lichenoid/interface dermatitis. Serum creatinine kinase was normal and an autoimmune screen, extended myositis panel and porphyria screen were negative. There was no clinical or radiological evidence of TCC in situ progression or other malignancy. Patch testing and phototesting were unavailable due to the COVID-19 pandemic. Durvalumab was stopped as the patient had TCC in situ only. The rash cleared with topical steroids and photoprotection. Over the following 3 years the patient had no further rashes. However, in August 2022, the TCC in situ progressed to metastatic TCC. After a course of cisplatin and gemcitabine chemotherapy, maintenance avelumab was started in May 2023. In August 2023 the patient developed rapid recurrence of the photosensitive rash after a prolonged episode of intense sun exposure through a car window without photoprotection. Skin biopsy again demonstrated an interface dermatitis with negative direct immunofluorescence. Repeat autoimmune, creatine kinase and porphyrin screens were negative. Topical steroids and strict photoprotection have enabled the patient to continue with avelumab for metastatic TCC. Photosensitivity in the context of malignancy may be a manifestation of paraneoplastic conditions such as dermatomyositis. However, associations with systemic anticancer therapies are increasingly being recognized. This is well established for selected targeted therapies including BRAF, epidermal growth factor receptor and Janus kinase inhibitors (e.g. vemurafenib, erlotinib, ruxolitinib) and in some the mechanism responsible is linked to second skin malignancies. There have been three reports of photosensitivity with anti-PD1 ICIs in recent years but, to our knowledge, this is the first report with anti-PDL1 ICIs. Whether this will also lead to second skin malignancies may become apparent with time. Finally, this case demonstrates the importance of recognizing new or rare cutaneous toxicities with anticancer treatments and their appropriate management in order to allow their continuation where possible, which is the ultimate goal of supportive dermato - oncology.

Recurrent Erythema Multiforme Induced by the Combination of Pembrolizumab and Radiation

Radiation Recall Dermatitis Following Treatment With Pembrolizumab: A Case Report and Review of the Literature

Radiation‐induced cutaneous squamous cell carcinoma showing a significant response to pembrolizumab: A case report

Radiation-Induced Laryngeal Mucous Membrane Pemphigoid

Delayed and localized pemphigus vulgaris after breast cancer radiotherapy

Radiation Recall Dermatitis in Patients Treated With Immune Checkpoint Inhibitors: A Case Report and Literature Review

Delayed and immediate cutaneous adverse events during pembrolizumab combination chemotherapy against cervical cancer: Case series

Refractory Bullous Pemphigoid in a Patient with Metastatic Lung Adenocarcinoma Treated with Pembrolizumab

BI02 Severe photosensitivity complicating anti-PDL1 checkpoint inhibitor treatment: an emerging immunotherapy-related skin toxicity

[A Case of Severe Skin Disorder during Pembrolizumab Treatment for Recurrent Maxillary Gingival Carcinoma]

Bullous Pemphigoid Associated With Pembrolizumab Therapy for Non-Small-Cell Lung Cancer: A Case Report

Non-small-cell Lung Cancer with Severe Skin Manifestations Related to Radiation Recall Dermatitis after Atezolizumab Treatment

Current Perspectives on Erythema Multiforme

Photodistributed erythema multiforme

Radiation Recall Dermatitis With Bruton Tyrosine Kinase Inhibitor Therapy

Durable Metastatic Melanoma Remission Following Pembrolizumab and Radiotherapy: A Case Report of Prophylactic Immunosuppression in a Patient with Myasthenia Gravis and Immune-Mediated Colitis

Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis

Radiation recall dermatitis after treatment of stage IV breast cancer with nivolumab: a case report

Case report: Lichenoid eruption under immunotherapy with MK-4830 and pembrolizumab in a breast cancer patient

Pemphigus vulgaris as an immune-related adverse event in recurrent metastatic esophageal squamous cell carcinoma treated with ipilimumab plus nivolumab: a case report and literature review

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab